RA0119

antibody from Oursmab

Targeting: CD47 IAP, MER6, OA3

Immunocytochemistry

Flow cytometry

Functional assay

Antibody data

Submit

Validation data

Product number: RA0119 - Provider product page
Provider: Oursmab
Product name: Lemzoparlimab (Biosimilar Reference Antibody) (CD47)
Antibody type: Monoclonal
Description: Lemzoparlimab (also known as TJC4) is an investigational, humanized monoclonal antibody designed to selectively target CD47, a cell-surface protein often overexpressed by cancer cells as a "don't eat me" signal. Unlike earlier anti-CD47 antibodies, lemzoparlimab is engineered with a differentiated binding epitope to minimize red blood cell (RBC) binding and agglutination, thereby reducing the hematologic toxicity commonly associated with CD47 blockade. By blocking the interaction between CD47 and its receptor SIRP¦Á on macrophages, it aims to promote the phagocytosis and elimination of tumor cells. It is being developed primarily for the treatment of hematologic malignancies and solid tumors, both as monotherapy and in combination regimens.
Reactivity: Human
Isotype: IgG
Vial size: 100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration: Bottled at the concentration indicated on the vial.
Storage: Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

CD47 protein structure - RA0119 shown in red.